Arcturus Therapeutics vs uniQure
ARCT and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARCT and QURE compare
uniQure is the larger company, worth 7.0 times as much as Arcturus Therapeutics ($1.7B against $238M).
uniQure grew revenue faster over the last twelve months (28.0% versus −68.7% for Arcturus Therapeutics).
Arcturus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −286% compared with −1155% at uniQure.
Arcturus Therapeutics scores higher on the StockData Score (9 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARCT | QURE |
|---|---|---|
| Size and price | ||
| Market cap | $238M | $1.7B |
| Share price | $8.36 | $23.81 |
| Change, 1 year | 2.8% | −20.9% |
| Change, 5 years | −77.1% | −19.7% |
| Beta (5Y) | 2.16 | 1.67 |
| Employees | 111 | 221 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.8× (better) | 81.9× |
| P/B | 1.4× (better) | 5.6× |
| FCF yield | −26.3% | −11.7% (better) |
| Fair value | $8.63 | $5.95 |
| Margin of safety | 3.1% (better) | −300% |
| Growth | ||
| Revenue growth (TTM) | −68.7% | 28.0% (better) |
| Revenue growth, 5Y average | 53.8% (better) | −15.6% |
| Profitability | ||
| Gross margin | – | 93.9% |
| Operating margin | −311% (better) | −1002% |
| Net margin | −286% (better) | −1155% |
| FCF margin | −205% (better) | −957% |
| Return on equity | −44.4% (better) | −89.0% |
| Return on invested capital | −534% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.17 (better) |
| Interest coverage | – | −3.5× |
| Current ratio | 6.68 | 11.52 (better) |
| Altman Z-score | −1.08 | −0.62 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 87.9% | 96.0% |
| Held by insiders | 8.1% | 2.1% |
| Insider net buying, 12 months | – | −$20.2M |
| Short interest, % of float | 20.7% | 12.5% |
Go deeper
- ARCT stock overview
- ARCT income statement
- ARCT valuation and score
- QURE stock overview
- QURE income statement
- QURE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.